From what 0 stock analysts predict, the share price for TransCode Therapeutics, Inc. (RNAZ) might decrease by 100% in the next year. This is based on a 12-month average estimation for RNAZ. Price targets go from $ to $. The majority of stock analysts believe RNAZ is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
TransCode Therapeutics, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that TransCode Therapeutics, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of RNAZ.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Emily Bodnar HC Wainwright & Co. | Buy | $3 | Reiterates | Aug 15, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $3 | Reiterates | May 29, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $3 | Reiterates | May 16, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $3 | Reiterates | Apr 16, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $3 | Reiterates | Apr 3, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $3 | Reiterates | Oct 24, 2023 |
Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 15, 2023 |
Emily Bodnar HC Wainwright & Co. | Buy | $6 | Maintains | Nov 15, 2022 |
Emily Bodnar HC Wainwright & Co. | Buy | $10 | Initiates | Jun 7, 2022 |
When did it IPO
2021
Staff Count
10
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Thomas A. Fitzgerald M.B.A.
Market Cap
$5.0M
In 2023, RNAZ generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RNAZ's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.